Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17095227rdf:typepubmed:Citationlld:pubmed
pubmed-article:17095227lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:17095227lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:17095227lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:17095227lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:17095227pubmed:issue3lld:pubmed
pubmed-article:17095227pubmed:dateCreated2007-1-22lld:pubmed
pubmed-article:17095227pubmed:abstractTextThe Type 1 PI3Kinases comprise a family of enzymes, which primarily phosphorylate PIP2 to give the second messenger PIP3, a key player in many intracellular signaling processes [Science, 2002, 296, 1655; Trends Pharmacol. Sci.2003, 24, 366]. Of the four type 1 PI3Ks, the gamma-isoform, which is expressed almost exclusively in leukocytes [Curr. Biol., 1997, 7, R470], is of particular interest with respect to its role in inflammatory diseases such as rheumatoid arthritis (RA) and chronic obstructive pulmonary disease (COPD) [Mol. Med. Today, 2000, 6, 347]. Investigation of a series of 4,6-disubstituted-4H-benzo[1,4]oxazin-3-ones has led to the identification of single-digit nanomolar inhibitors of PI3Kgamma, several of which had good cell based activity and were shown to be active in vivo in an aspectic peritonitis model of inflammatory cell migration.lld:pubmed
pubmed-article:17095227pubmed:languageenglld:pubmed
pubmed-article:17095227pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17095227pubmed:citationSubsetIMlld:pubmed
pubmed-article:17095227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17095227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17095227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17095227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17095227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17095227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17095227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17095227pubmed:statusMEDLINElld:pubmed
pubmed-article:17095227pubmed:monthFeblld:pubmed
pubmed-article:17095227pubmed:issn0960-894Xlld:pubmed
pubmed-article:17095227pubmed:authorpubmed-author:DudleyDavid...lld:pubmed
pubmed-article:17095227pubmed:authorpubmed-author:MobleyJames...lld:pubmed
pubmed-article:17095227pubmed:authorpubmed-author:LanniThomas...lld:pubmed
pubmed-article:17095227pubmed:authorpubmed-author:GreeneKeri...lld:pubmed
pubmed-article:17095227pubmed:authorpubmed-author:KolzChristine...lld:pubmed
pubmed-article:17095227pubmed:authorpubmed-author:ParaKimberly...lld:pubmed
pubmed-article:17095227pubmed:authorpubmed-author:VisnickMelean...lld:pubmed
pubmed-article:17095227pubmed:authorpubmed-author:BaginskiTheod...lld:pubmed
pubmed-article:17095227pubmed:authorpubmed-author:LiimattaMarya...lld:pubmed
pubmed-article:17095227pubmed:issnTypePrintlld:pubmed
pubmed-article:17095227pubmed:day1lld:pubmed
pubmed-article:17095227pubmed:volume17lld:pubmed
pubmed-article:17095227pubmed:ownerNLMlld:pubmed
pubmed-article:17095227pubmed:authorsCompleteYlld:pubmed
pubmed-article:17095227pubmed:pagination756-60lld:pubmed
pubmed-article:17095227pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:17095227pubmed:meshHeadingpubmed-meshheading:17095227...lld:pubmed
pubmed-article:17095227pubmed:meshHeadingpubmed-meshheading:17095227...lld:pubmed
pubmed-article:17095227pubmed:meshHeadingpubmed-meshheading:17095227...lld:pubmed
pubmed-article:17095227pubmed:meshHeadingpubmed-meshheading:17095227...lld:pubmed
pubmed-article:17095227pubmed:meshHeadingpubmed-meshheading:17095227...lld:pubmed
pubmed-article:17095227pubmed:meshHeadingpubmed-meshheading:17095227...lld:pubmed
pubmed-article:17095227pubmed:meshHeadingpubmed-meshheading:17095227...lld:pubmed
pubmed-article:17095227pubmed:meshHeadingpubmed-meshheading:17095227...lld:pubmed
pubmed-article:17095227pubmed:meshHeadingpubmed-meshheading:17095227...lld:pubmed
pubmed-article:17095227pubmed:meshHeadingpubmed-meshheading:17095227...lld:pubmed
pubmed-article:17095227pubmed:meshHeadingpubmed-meshheading:17095227...lld:pubmed
pubmed-article:17095227pubmed:meshHeadingpubmed-meshheading:17095227...lld:pubmed
pubmed-article:17095227pubmed:meshHeadingpubmed-meshheading:17095227...lld:pubmed
pubmed-article:17095227pubmed:meshHeadingpubmed-meshheading:17095227...lld:pubmed
pubmed-article:17095227pubmed:year2007lld:pubmed
pubmed-article:17095227pubmed:articleTitleDesign and synthesis of phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3Kinasegamma.lld:pubmed
pubmed-article:17095227pubmed:affiliationChemistry Department, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA. Thomas.Lanni@pfizer.comlld:pubmed
pubmed-article:17095227pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:17095227lld:chembl